TY  - CHAP
M1  - Book, Section
TI  - Pulmonary Venous Thromboembolism
A1  - Fitzpatrick, Meghan E.
A1  - Prendergast, Niall T.
A1  - Rivera-Lebron, Belinda
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
Y1  - 2022
N1  - 
T2  - Current Medical Diagnosis & Treatment 2022
AB  - KEY  CLINICAL  UPDATES  IN  PULMONARY  VENOUS  THROMBOEMBOLISMDirect-acting  oral  anticoagulants  are  recommended  as  first-line  anticoagulation  for  most  patients.Discontinuation  of  anticoagulation  may  be  considered  after  3  months  for  patients–  With  major  transient/reversible  risk  factors  (such  as  fracture  of  lower  limb;  hip  or  knee  surgery)–  Who  were  hospitalized  because  of  heart  failure,  atrial  fibrillation,  or  myocardial  infarction.Guidelines  support  systemic  thrombolysis  for  high-risk  or  massive  PE  (hemodynamically  unstable)  with  low  risk  of  bleeding.Intermediate-risk  or  submassive  PE  patients  have  a  significant  decrease  in  incidence  of  hemodynamic  collapse  but  do  not  have  a  mortality  benefit  with  thrombolytic  therapy.They  do,  however,  have  an  increase  in  major  hemorrhagic  complications,  including  intracranial  hemorrhage.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1186013018
ER  -